A Study to Determine if Technosphere® Inhalation Powder (FDKP) Causes ECG Changes (QTc) Following the Medication's Inhaled Administration.

Inclusion Criteria: * Pulmonary Function Tests (PFTs) results within study specified limits. * Female subjects of childbearing potential must be non-pregnant and non-lactating and have a negative serum pregnancy test prior to enrollment into the trial. * Body Mass Index = 19 and = 30 kg/m2 * Absence of recent drug or alcohol abuse * Able to provide written informed consent, follow study procedures and remain in-patient for the entire treatment period * Non-smoking (\> 6 months) Exclusion Criteria: * History of significant renal, pulmonary, rheumatological, hematological, neurological or psychiatrics disorder * Clinically significant major organ disease * Evidence or history of clinically significant allergies (except for untreated, asymptomatic, seasonal allergies at time of dosing); * Current or previous chemotherapy or radiation therapy that could cause lung toxicity * History of diabetes or taking any medications to treat diabetes * Clinically significant abnormal findings on physical exam, ECG, vital signs, clinical laboratory testing and medical history * Hypokalemia (calcium below lower limit of normal). * Previous exposure to Technosphere® Inhalation Powder * Participation in another clinical trial of an investigational drug or device within 30 days prior to Visit 3 * Significantly excessive consumption of food or beverages with xanthine or caffeine * Unwilling to avoid alcohol 48 hours prior to study enrollment and during study * Unwilling to avoid strenuous activity for 48 hours prior to study enrollment and during study * Positive HIV or Hepatitis test * Any acute illness or fever within 72 hours of study dosing * Medication use (with exception of acetaminophen and hormonal birth control) or herbal use within 7 days of Visit 2 * Unwillingness to remain in a quiet, controlled environment (i.e., no TV, music, games, etc during specific timepoints) or unwilling to remain supine during specific timepoints * Unwillingness to consume a study-specific diet * Blood donation within 8 weeks prior to Visit 2 * History of chronic obstructive pulmonary disease (COPD), clinically proven asthma and/or any other clinically important pulmonary disease confirmed by pulmonary function testing and/or radiological finding * Active respiratory infection or persistent symptoms of such infection * History of risk factors for Torsades de pointes (TdP) \[e.g., heart failure, hypokalemia, family history (parents or siblings) of Long QT Syndrome\], history of fainting, unexplained loss of consciousness or convulsions * History of cardiac arrhythmia, of taking anti-arrhythmia drugs, significant cardiovascular dysfunction, myocardial dysfunction, cardiac surgery, transient attacks of ischemia or cerebrovascular accidents * An abnormal screening ECG which is interpreted by the Clinical Site Investigator to be clinically significant * Sustained supine resting systolic blood pressure \> 140 mm Hg or \< 100 mm Hg and /or diastolic blood pressure \>95 mm Hg at study entry Baseline pulse rate of \< 45 beats per minute or \> 100 beats per minute